MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Diabetes Obesity and Metabolism
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

602 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
602 works in the cohort · of 4,299,418page 11 of 13

Labels cover 1 of 602 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 602 of 602 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( <scp>RACELINES</scp> ): A randomised, double‐blind trial
Michaël J.B. van Baar, Marcel H.A. Muskiet, Rosalie A. Scholtes, Daan J. Touw, Max Nieuwdorp, Mark H.H. Kramer +5 more
2025· article· en· Diabetes Obesity and Metabolism· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affunlabeled
Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of <scp>ONWARDS</scp> 1–5
Tina Vilsbøll, Ariel Fu, Monika Kellerer, Bharath Kumar, Stinne Byrholdt Søgaard, Ronald Goldenberg
2025· article· en· Diabetes Obesity and Metabolism· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
← previousnext →

How this was built: Screen · Findings · About